Pharma-Bio Serv (PBSV) director awarded 20,000 stock options on Form 4

Rhea-AI Filing Summary

Pharma-Bio Serv, Inc. director Howard Spindel reported a new stock option grant. On January 10, 2026, he was awarded 20,000 stock options with an exercise price of $0.54 per share, each option corresponding to one share of common stock.

The options vest in two equal installments on July 10, 2026 and July 10, 2027, meaning half become exercisable on each of those dates. Following this grant, Spindel beneficially owns 20,000 derivative securities, held directly, according to the report.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SPINDEL HOWARD

(Last) (First) (Middle)

7000 WEST PALMETTO PARK ROAD

SUITE 503

(Street)

BOCA RATON FL 33433

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pharma-Bio Serv, Inc. [ PBSV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.54	01/10/2026		A		20,000		(1)	01/10/2031	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. The option vests in two equal installments on July 10, 2026 and July 10, 2027.

	/s/ Howard Spindel	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pharma-Bio Serv (PBSV) report on Form 4?

The filing reports that director Howard Spindel received a grant of 20,000 stock options on January 10, 2026, each option linked to one share of Pharma-Bio Serv common stock.

What is the exercise price of Howard Spindels Pharma-Bio Serv (PBSV) stock options?

The stock options granted to Howard Spindel have an exercise price of $0.54 per share, as disclosed in the Form 4.

How many Pharma-Bio Serv (PBSV) options does Howard Spindel own after this grant?

After the reported transaction, Howard Spindel beneficially owns 20,000 derivative securities (stock options) of Pharma-Bio Serv, held directly.

What is the vesting schedule for Howard Spindels Pharma-Bio Serv stock options?

The options vest in two equal installments on July 10, 2026 and July 10, 2027, with half of the 20,000 options vesting on each date.

What is Howard Spindels relationship to Pharma-Bio Serv (PBSV)?

Howard Spindel is reported as a director of Pharma-Bio Serv, Inc. on the Form 4, and the filing is for one reporting person.

Is Howard Spindels Pharma-Bio Serv option grant reported as direct or indirect ownership?

The Form 4 reports the 20,000 stock options as held under direct ownership (D), with no indirect ownership entity listed.